['hypercholesterolemia']
['rosuvastatin', 'ezetimibe']

        Inclusion Criteria:

          1. 19 ~ 79 years old

          2. Patients who confirmed hypercholesterolemia.

          3. Patients who requiring drug therapy according to NCEP ATP(National Cholesterol
             Education Program Adult Treatment Panel) III Guideline at Visit2.

          4. Patients with Triglyceride< 400 at Visit 2.

          5. Patients who have a wash-out period over 4 weeks for other drugs that can affect lipid
             profile.(Patients who have lipid regulators should have washout period over six weeks)

          6. Patients who agreed to participate in the trial

        Exclusion Criteria:

          1. Patients who have a history of myopathy or rhabdomyolysis by statin treatment or
             hypersensitivity to statin HMG CoA(3-hydroxy-3-methylglutaryl-coenzyme) reductase
             inhibitors) or ezetimibe.

          2. A heavy alcohol consumer. (alcohol > 25 units/week)

          3. Patients with severe renal disease. (creatinine ≥ 2.0 mg/dL)

          4. Patients with active liver disease and AST(aspartate transaminase) or ALT(alanine
             transaminase) > 2 times of upper limit of normal range.

          5. Patients with CPK(creatine phosphokinase) > 2 x upper limit of normal range.

          6. Patients who have a endocrine or metabolic diseases known to affect the serum
             phospholipid or lipoprotein.

          7. Patients with HIV(human immunodeficiency virus positive.

          8. Patients who have a acute arteriopathy.

          9. Patients with uncontrolled hypertension.

         10. Patients who have hereditary problems such as galactose intolerance, Lapp lactase
             deficiency, or glucose-galactose malabsorption.

         11. Patients who have a drugs absorption disorder by gastrointestinal surgery or
             gastrointestinal disorder.

         12. Patients with tumor.

         13. Patients who have hormonal therapy.

         14. Pregnancy or breastfeeding patients who don't agree to use adequate contraception.

         15. Patients who are judged unsuitable to participate in this study by investigator.

         16. Patients taking other clinical trial drugs within 30 days from the time of visit for
             screening.
      